If you have been reading about REV-ERB agonist and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-11-26. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white solid | Visual inspection is not sufficient for identity. |
| Solubility | Soluble in DMSO and ethanol | Low solubility in water. |
| Typical storage | -20 °C, desiccated, dark | Protect from repeated temperature changes. |
| Common analytical method | LC-MS or HPLC-UV | Reference standard required for comparison. |
| Common synonyms | SR9009; Stenabolic; REV-ERB agonist | Vendor naming may vary. |
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
The reaction is reliable and proceeds to completion. Less unreacted starting material will simplify analysis. Also, this allows a small amount of analyte to be used. The reaction is general, allowing a wide range of substrates, yet specific to a single functional group, reducing complicating interference. The products are relatively stable, and form no degradation products within a reasonable period, facilitating analysis. Some examples of good derivatization reactions are the formation of esters and amides via acyl chlorides.
T4 (levothyroxine) is almost always preferred over T3 (liothyronine) when treating hypothyroidism. Treatment with T3 alone is not recommended, as it causes increased and potentially unsafe blood levels of free T3 (FT3). Combination treatment of hypothyroidism with T4 and T3 is generally only considered when treatment with T4 alone does not sufficiently resolve symptoms. As there is no evidence showing that combination treatment with T4 and T3 benefits patients, this approach is controversial, but it is supported by current guidelines of the European Thyroid Association and the British Thyroid Association for patients who do not respond at all to treatment with T4 alone.
==== Misuse of prescription medication ==== Misused prescription medicine, such as opioids, can lead to heroin use and dependence. The number of death from illegal opioid overdose follows the increasing number of death caused by prescription opioid overdoses. Prescription opioids are relatively easy to obtain. This may ultimately lead to heroin injection because heroin is cheaper than prescribed pills.
== Early life == Miguel A. Ondetti was born in Buenos Aires, Argentina; on May 23, 1930. Ondetti's background was Italian. His mother was an Argentine-born Italian, while his father's family had first emigrated from Italy to Paris, then to Argentina. Despite this, Ondetti considered himself a "first-generation Argentine". Ondetti's father practiced a family craft of making garden furniture from cement that imitated tree trunks. Following the mid-1930s he became a night watchman. His mother was a housewife who cared for Miguel and his only brother, who is two years older. Ondetti's first experience with chemistry was experimenting with his older brother. Miguel tried to electroplate a knife using a copper sulfate solution, only to shock himself.
Sources: en.wikipedia.org
=== Stabilization that provides partial support or protection === Structural weakness and damage must be supported in textiles, especially areas such as the top of tapestries and the shoulders of garments
==== MeSH D12.125.837 – serine ==== MeSH D12.125.837.075 – azaserine MeSH D12.125.837.150 – cycloserine MeSH D12.125.837.225 – droxidopa MeSH D12.125.837.300 – enterobactin MeSH D12.125.837.800 – phosphoserine
=== Relation to athletic performance === Polycythemia is theorized to increased performance in endurance sports due to the blood being able to store more oxygen. This idea has led to the illegal use of blood doping and transfusions among professional athletes, as well as use of altitude training or elevation training masks to simulate a low-oxygen environment. However, the benefits of altitude training for athletes to improve sea-level performance are not universally accepted, with one reason being athletes at altitude might exert less power during training.
The library of oligonucleotides must be extremely diverse and not contain linear, incapable of providing a stable spatial arrangement, and double-stranded structures; due to these limitations, oligonucleotide libraries can cover the diversity of only ~106 sequences. This means that existing aptamers may not fully cover the diversity of target molecules or may not have optimal properties due to limitations of the underlying method. To yield the best possible aptamers one must maximize the effectiveness of the discovery process and the library itself. RNA and DNA secondary structure prediction by dynamic programming algorithms such as RNAfold (ViennaRNA) and by machine learning models such as SPOT-RNA, MXfold2 provides the opportunity to assess the ability of sequences in the primary library to fold into complex structures, allowing for the selection of only the most promising sequences from the entire pool. However, these algorithms are low-performance, making them poorly suited for this task. For this reason, algorithms like Ufold from the University of California and AliNA from Xelari Inc. have been developed, which demonstrate a significant increase in computational speed due to their faster architecture, and can be applied for preliminary in silico analysis of these libraries.
During the 2024 presidential election, Moore was a member of the Biden-Harris Campaign National Advisory Board and campaigned for President Joe Biden in Wisconsin and Georgia. He also defended Biden from calls to drop out of the presidential election amid the first 2024 presidential debate, highlighting Biden's accomplishments in office while conceding that the debate was a "rough night" for the president. After Biden withdrew from the race on July 21, 2024, Moore endorsed and campaigned for Vice President Kamala Harris. During the 2024 United States Senate election in Maryland, Moore endorsed Prince George's County Executive Angela Alsobrooks in the Democratic primary over U.S. representative David Trone. He played an active role in campaigning against Republican nominee and former governor Larry Hogan in the general election, with several of his top advisors leaving their positions in the Moore administration to form a political action committee called Unity First PAC to support Alsobrooks and other Democratic nominees downballot.
Sources: en.wikipedia.org
== Systemic effects == An infectious organism can escape the confines of the immediate tissue via the circulatory system or lymphatic system, where it may spread to other parts of the body. If an organism is not contained by the actions of acute inflammation, it may gain access to the lymphatic system via nearby lymph vessels. An infection of the lymph vessels is known as lymphangitis, and infection of a lymph node is known as lymphadenitis. When lymph nodes cannot destroy all pathogens, the infection spreads further. A pathogen can gain access to the bloodstream through lymphatic drainage into the circulatory system. When inflammation overwhelms the host, systemic inflammatory response syndrome is diagnosed. When it is due to infection, the term sepsis is applied, with the terms bacteremia being applied specifically for bacterial sepsis and viremia specifically to viral sepsis. Vasodilation and organ dysfunction are serious problems associated with widespread infection that may lead to septic shock and death.
Naval Postgraduate School academic Edward A. Olsen, British politician David Alton, York University professor Hyun Ok Park, and University of Southern California professor David C. Kang used the term to refer to tensions between North Korea and South Korea, which have been divided since the end of World War II in 1945. They interchangeably called it the "Korean Cold War". In August 2019, the North Korean government said that further US–South Korean military cooperation would prompt North Korea to "trigger a new cold war on the Korean Peninsula and in the region." China's Defense Ministry spokesman Geng Yansheng, The Diplomat editor Shannon Tiezzi, and The Guardian columnist Simon Tisdall used the term to refer to tensions between China and Japan.
== Early life == Louis Szathmary was born on June 2, 1919, on a train heading from Transylvania to Budapest as his parents fled the post World War I Hungarian–Romanian War. He earned his master's degree in journalism and doctorate in psychology from the University of Budapest before being drafted into the Hungarian army to serve in World War II. Szathmary originally served as a psychologist to Hungarian Army men, before transferring positions to Army private, where he wrote manuals, including one for cooking. Subsequently, he enrolled in a Hungarian chef's school and took an advanced course.
Furthermore, specific LTBP isoforms have a propensity to associate with specific LAP•TGF-β isoforms. For example, LTBP-4 is reported to bind only to TGF-β1, thus, mutation in LTBP-4 can lead to TGF-β associated complications which are specific to tissues that predominantly involves TGF-β1. Moreover, the structural differences within the LAP's provide different latent TGF-β complexes which are selective but to specific stimuli generated by specific activators.
Sources: en.wikipedia.org
Liquid chromatography–mass spectrometry is common for identity and purity checks. High-performance liquid chromatography with ultraviolet detection can also be used. Both methods require a suitable reference standard.
The solid is usually kept desiccated at -20 °C or lower and protected from light. Stock solutions are aliquoted to limit freeze–thaw cycles. Aqueous solutions are not generally recommended for long-term storage.
Laws differ by country and by intended use. It is not an approved medicine, and many vendors sell it as a research chemical. Purchasers are responsible for confirming local restrictions.
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.